Urodynamix Technologies Ltd. (URO.V) Announces Change in Directors and Officers

Urodynamix Technologies Ltd. (URO.V) Announces Change in Directors and Officers
VANCOUVER, BRITISH COLUMBIA--(Marketwire - December 20, 2010) - Urodynamix Technologies Ltd. (TSX VENTURE: URO) today announces that Dave Rankin and David Raffa have been appointed to its Board of Directors and that Pierre Leduc, Barry Allan and Tanner Philp have stepped down as directors.

Dave Rankin is co-founder and VP Business Development of Endurance Wind Power. Endurance is a rapidly growing local manufacturer of advanced wind turbines designed specifically for distributed wind power applications. Dave has an MBA from the University of Western Ontario and currently sits on the Board of three other public companies.

David Raffa is Chief Operating Officer and Partner of Lions Capital. David was previously a corporate finance lawyer specializing in the technology sector. Having retired from the practice of law to co-found Lions Capital, David currently serves as a director, officer or advisory board member of a number of private and public technology companies. David has a Bachelor of Science degree from Simon Fraser University and a Bachelor of Laws degree from Osgoode Hall Law School.

The new Board has appointed Jim Heppell Chairman of the Board and CEO; and David Raffa as President and Secretary.

"I would like to personally thank Barry Allen and Dr. Luya Li for their tenacity and hard work in closing the sale of the Company's assets for $2.1 million," said Jim Heppell. "If not for their efforts, we would not have this opportunity to rebuild shareholder value. I would also like to acknowledge Pierre Leduc who, as Chairman of the Board, led the Company during a particularly challenging time." 

Urodynamix Technologies Ltd.
Jim Heppell


Read at BioSpace.com 

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.